COVID-19 Vaccine Study Highlights Effectiveness Amid Controversy

A recent study on the effectiveness of COVID-19 vaccines has finally been shared with the public. This information had been delayed in publication by a government health journal. According to findings published by JAMA Network Open, the vaccine showed approximately 55% effectiveness in preventing COVID-19-related hospitalizations. It also reduced trips to emergency departments and urgent care clinics by 50%.

While it might not be surprising that vaccines function well, the study gained attention after being initially withheld. Political appointees in the Trump administration chose not to publish it in the Centers for Disease Control and Prevention (CDC) publication. They cited concerns about the study’s design, fearing it might lead to flawed results due to false assumptions.

Many public health researchers defended the study’s design, arguing it has been used effectively for decades. They claim it presents the best method to understand vaccine effectiveness as the virus evolves. Natalie Dean, a biostatistics expert at Emory University, emphasized the importance of ongoing research to measure vaccine effectiveness. Her commentary accompanied the study’s release.

Initially scheduled for release in the CDC’s Morbidity and Mortality Weekly Report, the research encountered delays after being flagged by Acting Director Jay Bhattacharya. Althea Grant-Lenzy, the CDC’s chief science officer, explained the decision didn’t end prospects for publication. The authors were free to submit the study to external journals after addressing the concerns noted.

The study utilized a “test-negative design.” This approach examines individuals hospitalized or visiting emergency rooms with respiratory illnesses, determining their vaccination status. By assessing the odds of a positive COVID-19 test, the research compares outcomes between vaccinated and unvaccinated individuals. This methodology has earned validation from several prominent journals, including Pediatrics and the New England Journal of Medicine.

Bhattacharya critiqued the methodology, pointing out potential biases due to assumptions and patient behavior differences. Concerns about results being affected by prior infections also surfaced. However, supporters of the methodology argue it effectively navigates who seeks care and that prior infection impact is minimal as many in the U.S. already encountered COVID-19.

The CDC convened a forum to discuss the methodology’s prospects and challenges. Biostatistician Martin Kulldorff, a noted critic, raised arguments against its application and advocated for longer-term studies. His stance, reminiscent of the Great Barrington Declaration’s anti-shutdown ideas, questioned including diverse disease groups in test-negative design studies.

Despite criticisms, the absence of a viable alternative led to continued endorsement from many experts. Kulldorff, who served on a federal vaccine advisory committee, eventually transitioned to a role at the Department of Health and Human Services.

The project received support from Howard Hughes Medical Institute’s Science Education Department and the Robert Wood Johnson Foundation. The Associated Press maintains full content responsibility.